Fig. 4
Evaluation of the antiproliferative ability of the therapeutic nanocomposites. A Cell viability of SKOV3 and B SKOV3TR cells treated with targeted HA-PTX/let-7a-pGNR@MSN and nontargeted PTX/let-7a-pGNR@MSN. C Therapeutic effects of various therapeutic nanocomposites on SKOV3TR cell proliferation: A, control; B, HA-miR let-7a-pGNR@MSN; C, HA-PTX-pGNR@MSN; D, PTX/let-7a-pGNR@MSN; E, HA-PTX/miR let-7a-pGNR@MSN. D Cellular viability assay using a PI and FDA double-staining protocol and E corresponding quantitative analysis of 24 h treatment with 100 μg/mL of various therapeutic nanocomposites: A, Control; B, HA-let-7a-pGNR@MSN; C, HA-PTX-pGNR@MSN; D, PTX/miR let-7apGNR@MSN; E, HA-PTX/miR let-7a-pGNR@MSN. Scale bar = 200 μm. F Western blotting was used to measure P-gp expression after 24 h treatment with 100 μg/mL of various therapeutic nanocomposites and G corresponding quantitative analysis: A, control (SKOV3 cells); B, control (SKOV3TR cells); C, HA-miR let-7a-pGNR@MSN; D, HA-PTX-pGNR@MSN; E, PTX/miR let-7a-pGNR@MSN; F, HA-PTX/miR let-7a-pGNR@MSN. HA, hyaluronic acid; PTX, paclitaxel; let-7a, lethal-7a; pGNR, polyethylene glycol-modified gold nanorod; MSN, mesoporous silica nanoparticle; FDA, fluorescein diacetate; PI, propidium iodide; P-gp, P-glycoprotein